{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrence&page=21", "query": { "condition": "Recurrence", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 9468, "total_pages": 947, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrence&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrence&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T03:03:10.157Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05107934", "title": "Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Pericarditis" ], "interventions": [ { "name": "RPH-104", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "R-Pharm Overseas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107934" }, { "nct_id": "NCT04709601", "title": "Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Urinary Tract Infections" ], "interventions": [ { "name": "Hiprex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "FEMALE", "summary": "50 Years to 85 Years · Female only" }, "enrollment_count": 14, "start_date": "2021-01-04", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04709601" }, { "nct_id": "NCT03252600", "title": "Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Primary Amyloidosis" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Elotuzumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2017-08-25", "completion_date": "2023-12-07", "has_results": false, "last_update_posted_date": "2023-01-25", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 5, "location_summary": "Duarte, California • Denver, Colorado • Atlanta, Georgia + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03252600" }, { "nct_id": "NCT04983407", "title": "Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "batiraxcept", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aravive, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-07-28", "completion_date": "2023-08-14", "has_results": false, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 17, "location_summary": "Santa Monica, California • Boca Raton, Florida • Tampa, Florida + 12 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04983407" }, { "nct_id": "NCT00107536", "title": "Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2005-10", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2015-04-29", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107536" }, { "nct_id": "NCT00895934", "title": "Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "gemtuzumab ozogamicin", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 52, "start_date": "2009-05", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2019-05-23", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 4, "location_summary": "Stanford, California • Bremerton, Washington • Seattle, Washington", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Bremerton", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00895934" }, { "nct_id": "NCT00028964", "title": "Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Drug/Agent Toxicity by Tissue/Organ" ], "interventions": [ { "name": "Chinese herbs", "type": "DIETARY_SUPPLEMENT" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2001-02", "completion_date": "2005-02", "has_results": false, "last_update_posted_date": "2011-02-23", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028964" }, { "nct_id": "NCT03452332", "title": "Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cervical Adenocarcinoma", "Advanced Vaginal Carcinoma", "Advanced Vulvar Carcinoma", "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma", "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma", "Metastatic Cervical Adenocarcinoma", "Metastatic Cervical Carcinoma", "Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Metastatic Vaginal Adenocarcinoma", "Metastatic Vaginal Carcinoma", "Metastatic Vulvar Carcinoma", "Recurrent Cervical Adenocarcinoma", "Recurrent Cervical Carcinoma", "Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Vaginal Cancer AJCC v8", "Stage III Vulvar Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Vulvar Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Vulvar Cancer AJCC v8", "Stage IIIC Vulvar Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Adenocarcinoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2018-07-18", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452332" }, { "nct_id": "NCT02482532", "title": "Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "tvs-CTL Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gary Doolittle", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 7, "start_date": "2016-10-06", "completion_date": "2021-09-13", "has_results": false, "last_update_posted_date": "2022-02-04", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 1, "location_summary": "Fairway, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02482532" }, { "nct_id": "NCT07418593", "title": "Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Pancreatitis", "Recurrent Acute Pancreatitis", "Exocrine Pancreatic Insufficiency" ], "interventions": [ { "name": "Pancreatic Enzyme Replacement Therapy", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "MBT1", "type": "DIAGNOSTIC_TEST" }, { "name": "MBT 2", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Anna Evans Phillips", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-04-20", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-24T03:03:10.157Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Pittsburgh, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07418593" } ] }